Background: Most children with primary immunodeficiencies (PIDs) now reach adulthood. However, few studies have evaluated their health status and health-related quality of life (HRQoL). Objective: To investigate long-term morbidity, the French Reference Center for PIDs initiated a prospective multicenter cohort: the French Childhood Immune Deficiency Long-term Cohort. The data collected were used to assess the physical health condition of patients who reached adulthood and the effect on their quality of life. Methods: Patients were asked to complete health status questionnaires. A severity score (grade 1 [mild] to grade 4 [lifethreatening]) was assigned to each health condition. The HRQoL of patients was compared with age-and sex-matched French normal values by using the 36-item Short-Form Survey (SF-36) HRQoL questionnaire. Results: Among 329 participants, the mean age at evaluation was 27.6 years, with a 21-year mean follow-up after diagnosis; 43% reported at least 1 grade 4 health condition, and 86% reported at least 1 grade 3 (severe) or 4 health condition.
Abbreviations used
1 Although an increasing number of patients are given a diagnosis of adult-onset PIDs, most of them are still given diagnoses during childhood. Many patients require lifelong therapy, either antibiotic or antifungal prophylaxis or immunoglobulin replacement therapy. 2, 3 Hematopoietic stem cell transplantation (HSCT) remains the only definitive cure for severe PIDs, although gene therapy has emerged as an alternative option for a currently limited and selected number of PIDs. 4, 5 Actually, PIDs are an ontological framework characterized by high clinical, biological, genetic, and therapeutic heterogeneity. Taken as a whole, they represent a vast group of conditions that are chronic, lifelong, serious, and likely to affect life expectancy. 6 Because survival is often considered the most important outcome in study designs, few studies have assessed the severity of health conditions. Previous reports have focused on either specific diseases 7 or specific complications concerning survivors with severe combined immunodeficiency who underwent transplantatiom. 8 In terms of health-related quality of life (HRQoL), most studies have focused on immunoglobulin replacement, investigating its effect on infection rates and the patient's well-being. 9, 10 The purpose of our study was to gain insight into how PIDs might affect patient health status by focusing on adults with PIDs diagnosed during childhood. Thus we used the French Reference Center for PIDs (CEREDIH, www.ceredih.fr) national registry and the nationwide network of clinicians (both pediatricians and adult physicians who are all trained in the management of patients with PIDs and work in university teaching hospitals). 11 The CEREDIH, which was established in France in 2005, runs a large national PID registry with a current minimal prevalence of 7.10 E25 inhabitants in the French population (see: www. ceredih.fr, last accessed January 10, 2016). 12 Here we investigate 329 adults given a diagnosis of PID during childhood and enrolled in a national survey with 889 participants (560 children and 329 adults). We address the prevalence and severity of health conditions and their effect on quality of life.
METHODS

Study cohort
The French Childhood Immune Deficiency Long-Term Study Group (F-CILSG) is a CEREDIH working party that conducts a multicenter prospective follow-up program enrolling participants who met all of the following criteria: (1) patient with a PID included in the CEREDIH registry, (2) clinical diagnosis of PID before 18 years of age, (3) alive and living in France, and (4) provision of written informed consent to participate in the study. Contact and recruitment of eligible participants by using a uniform procedure began in August 2013. The French Childhood Immune Deficiency Long-term Cohort (F-CILC) questionnaires (along with a cover letter explaining the objectives of the study), study information documents, and informed consent forms were sent by post to all eligible French patients. When the questionnaire was not returned within 3 weeks' time, a trained interviewer contacted the patient by telephone to both verify that the questionnaire had been received and attempt to secure participation. Completed questionnaires received at the coordinating center were computerized according to the F-CILSG protocol.
Patients were considered ''participants'' when the questionnaire was completed and returned along with the written informed consent document signed by the patient. Patients were considered ''lost to follow-up'' after extensive efforts failed to locate them. Patients were considered a ''nonparticipant'' when either they declined participation verbally by telephone or in writing or indicated their willingness to participate but did not return a completed questionnaire and signed informed consent document.
The study was financed by the French National Programme for Clinical Research (PHRC; Ministry of Health, EudraCT trial no. 2012-A0033-35) and has been approved by a review board (Comit e National Informatique et Libert es). We received written consent from all participants included in our study. The local ethics committee (Comit e de Protection des Personnes Sud-M editerran ee V, France; trial no. 12.024) and the Comit e Consultatif sur le Traitement de l'Information de Recherche dans la Sant e (CCTIRS trial no. 12.681) approved this study.
Assessment of patients' PIDs
Information concerning demographic data, clinical and genetic PID diagnosis, date of onset of PID symptoms, date of clinical diagnosis of PID, therapy history data (particularly immunoglobulin replacement and HSCT), and a set of clinical laboratory results were obtained from the CEREDIH registry, which was updated on an annual basis.
According to the criteria of the International Union of Immunological Society, PIDs were classified into 6 subgroups: predominantly T-cell deficiencies, predominantly antibody deficiencies, phagocytic disorders, immune dysregulation (ie, familial hemophagocytic lymphohistiocytosis and immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), other well-defined PIDs, and complement deficiencies. 1 
Assessment of health conditions
Participants completed the adult F-CILC questionnaire. This selfadministered questionnaire, which was printed in French, included 638 items covering the following domains: sociodemographic characteristics (eg, education, employment, and marital condition), PID diagnosis and family history, medical care practices (eg, immunoglobulin replacement and HSCT), transition to adult care facilities, and physical health condition (eg, cardiac; respiratory; ear, nose, and throat [ENT]; gastrointestinal; dermatologic; genitourinary; musculoskeletal; neurologic; endocrinopathy; surgery; and malignancy). The 320 items concerning physical health conditions were based on the questionnaire previously published for the Cancer Childhood Survivor Study and then adapted to the PID context. It has been successfully used to describe chronic health conditions in childhood cancer survivors, thereby confirming that patients are able to accurately report the occurrence of adverse medical conditions. 13, 14 Each health condition was self-rated by the patient according to a 4-grade scale: grade 1, mild; grade 2, moderate; grade 3, severe; and grade 4, lifethreatening/disabling.
To avoid undergrading, a medical evaluation of each health condition was also performed, and the higher of the 2 grades was selected for the final evaluation. Medical grading was performed applying the Common Terminology Criteria for Adverse Events (CTCAE) v3.0: grade 1, mild; grade 2, moderate; grade 3, severe; and grade 4, life-threatening/disabling (grade 5 5 death was not applicable in this study). 15 When a particular condition was not listed (eg, aspergillosis and pneumocystosis), a multidisciplinary group assessed severity based on a 4-grade scale. In situations in which we were unable to distinguish between the 4 grades because of a lack of information, the lower score was selected.
Assessment of HRQoL
All patients were asked to complete the 36-item Short-Form Survey (SF-36) questionnaire, a reliable instrument used to assess self-perceived health status in adults. 16 The SF-36 is comprised of 36 items describing 8 dimensions: physical functioning, social functioning, role limitations caused by physical health problems, role limitations caused by emotional problems, general mental health, vitality, bodily pain, and general health perceptions. Two summary composite scores were then generated: the physical composite score and the mental composite score. All scores ranged between 0 and 100, with higher scores indicating better HRQoL. The French general population reference values are available for sex-and age-matched comparison purposes. 17 
Statistical analyses
We determined the prevalence and severity of physical health conditions by using 2 end points: (1) life-threatening/disabling (grade 4), which was reported either by the patient or through medical assessment (according to CTCAE score), and (2) severe or life-threatening/disabling (grade 3-4), which was reported either by the patient or through medical assessment. These 2 events have been used throughout the analysis.
Statistical analyses were performed with SPSS software (version 20.0; SPSS, Chicago, Ill). Data are expressed as numbers and percentages or means 6 SEMs. The paired student t test was used to compare the SF-36 mean scores reported by patients with those obtained for age-and sex-matched French control subjects. All quantitative variables were compared by using the Student t test, ANOVA, or Kruskal-Wallis nonparametric test, as appropriate. The significance threshold was set as a P value of less than .05.
RESULTS
Patients' characteristics
Between June 1, 2013, and December 31, 2014, 1561 patients identified in collaborating CEREDIH institutions were contacted (see Fig E1 in this article's Online Repository at www.jacionline. org). A completed questionnaire and a signed informed consent form were obtained for 889 (56%) participants. We observed no significant difference between patients included in the F-CILC and eligible patients who were not included with regard to sex, PID diagnosis, age at PID diagnosis, and age at study participation.
Among the 889 participants, 329 were adults older than 18 years, and all were included in the following analyses. Table I displays the characteristics of these 329 adult patients. Mean age at PID diagnosis and at the time of the study was 6.6 6 0.47 and 27.6 6 0.49 years, respectively. The mean interval from the date of PID diagnosis to the date of completion of the questionnaire was 20.9 years. Of the 329 adult participants, 58 (17.6%) had undergone HSCT as part of PID treatment. A total of 142 patients received immunoglobulin replacement (including 11 patients with HSCT) administrated either intravenously (46% of patients) or subcutaneously (54% of patients). Sixty-five percent of patients underwent therapy at home, and 80% were the principal decision makers when choosing replacement therapy. Regarding access to adult health care, 87% of patients were followed by an immunologist, whereas 16% were monitored by a pediatrician. Of the 55 adults who continued to be followed by their pediatrician, the majority (83%) wished to delay the transition to adult health care, and 15 patients had received HSCT. Among the 269 patients currently followed by the adult team, 86% were satisfied with their transition. During the past year, the consultation frequency was quarterly, biannually, and annual in 22.5%, 33%, and 27% of patients, respectively. Finally, during the same period, 90 patients were hospitalized, two thirds once. Eighty-six percent of patients experienced at least 1 grade 3 (severe) or grade 4 health condition. The percentage of patients with 1, 2, 3, 4, and 5 or more grade 3 to 4 health conditions was 18.5%, 18.2%, 15.5%, 12.0%, and 21.2%, respectively. Fig 1 shows the frequency of the different health conditions according to the following categories: respiratory system, ENT, gastrointestinal, oral, genitourinary, neurologic, musculoskeletal, surgery, malignancy, dermatologic, cardiac, and endocrine. The most frequent grade 4 health conditions involved 3 categories: surgery (20%; 95% CI, 15.7% to 24.6%), respiratory (10%; 95% CI, 6.6% to 13.2%), and intestinal (9%; 95% CI, 6.3% to 12.9%). The bulk of grade 3 or 4 health conditions involved the following 8 categories: surgery (49.5%; 95% CI, 44% to 55%), respiratory (43%; 95% CI, 37.5% to 48.4%), ENT (36%; 95% CI, 15.1% to 23.9%), intestinal (34%; 95% CI, 29% to 37.5%), dermatological (24%; 95% CI, 19.6% to 29.1%), oral (19%; 95% CI, 15.1% to 23.9%), neurological (18.5%; 95% CI, 14.9% to 23.6%), and musculoskeletal (18%; 95% CI, 14.6% to 23.3%). Furthermore, 7.6% of the patients reported a malignancy, including lymphoma (n 5 13), leukemia (n 5 3), skin malignancies (basal cell carcinoma, n 5 2; melanoma, n 5 1), breast cancer (n 5 1), bowel cancer (n 5 2), bone tumor (n 5 2), and brain tumor (n 5 1). Almost 50% of participants report a grade 3 to 4 surgery, among which were splenectomy, surgical drainage of an abscess, lobectomy, cardiac surgery, appendectomy, and ENT surgery. 
Health condition outcomes
Quality of life
Among 329 participants, 309 completed the SF-36 questionnaire. Overall, PIDs had a strong negative effect on both the physical and mental domains of quality of life in these adults. As reported in Table II , when compared with French population normal values, adults with PIDs scored significantly lower for all domains of HRQoL.
According to the PID diagnosis (Table III) , no significant difference was observed in the physical or mental composite scores. Furthermore, no significant difference was observed in most subscales, with the exception of the mental health subscale (higher scores were reported for immune regulation diseases and predominantly antibody disorders) and general health subscale (a better perception in combined immunodeficiency and immune regulation diseases). Table IV shows HRQoL according to whether the patient had received HSCT. Although the mental composite scores were comparable, there was a significant difference in the physical composite score and general health subscale, which displayed significantly higher scores in the group undergoing transplantation.
Otherwise, quality of life was significantly diminished when hospitalization occurred during the past year (see Table E1 in this article's Online Repository at www.jacionline.org). Conversely, HRQoL was not affected by the current prophylactic therapy (immunoglobulin replacement and antimicrobial therapy vs none) or duration of the disease (see Tables E2-E5 in this article's Online Repository at www.jacionline.org).
The quality-of-life outcome was strongly associated with the number of health conditions experienced by the patient. When only grade 4 health conditions were considered, the association was highly significant for both physical and mental composite scores, as well as for all respective subscales. Patients who had experienced at least 1 grade 4 health condition were more likely to report poor HRQoL than patients who had not, and the scores were even lower with at least 2 health conditions (Fig 2) . The same association was found for patients with grade 3 or 4 health conditions (Fig 3) . However, as shown in Figs 2 and 3 , the threshold for poor quality of life appeared to be at least 2 health conditions.
DISCUSSION
The F-CILSG is a CEREDIH working party that conducts a multicenter prospective follow-up program addressing the longterm health outcomes of patients with PIDs. In this report we focused on health conditions in 329 adults with a diagnosis of PID during childhood, with a mean interval between diagnosis and study evaluation of 20.3 years. The severity of each health condition was evaluated by using a 4-grade scoring system according to both patient self-perception and the CTCAE.
To our knowledge, this is the first study to describe the health conditions of adults with a PID diagnosed during childhood at a population level. We show that the prevalence of severe or life-threatening health conditions is very high in adults with PIDs, particularly concerning surgery, respiratory, gastrointestinal, ENT, and dermatological conditions. Only fewer than 15% of adults with PIDs had never experienced severe or life-threatening conditions. Additionally, these patients were more likely to have multiple conditions. We also found that the prevalence of cancer was markedly increased considering the young age of our population. Finally, this heavy burden of health conditions markedly affected patient' quality of life compared with that of the general population. There are several limitations to keep in mind when interpreting these findings. First, our response rate (329/647 adults) raises the question of the representativeness of our cohort, especially because we could not compare the 2 groups regarding socioeconomic level, marital status, or educational level because of the lack of information regarding the nonparticipating population. Furthermore, the conditions were self-reported without external verification, with the exception of malignancy. Additionally, our list of conditions was not exhaustive, especially for mental health, and some conditions that remain clinically silent might have been underreported. Furthermore, no data were collected concerning recent occurrences of acute stress, which have been shown to affect HRQoL. However, it is important to note that the use of self-reported questionnaires has been shown to be a very accurate method in other comparable settings, such as children with malignancy in the Cancer Childhood Survivor Study. 13, 14 Some studies have assessed the frequency and severity of health conditions in a subgroup of PIDs, such as severe combined immunodeficiency or chronic granulomatous disease 7, 8 in children and agammaglobulinemia or common variable immunodeficiency (CVID) 18, 19 in adults. In the largest cohort of CVID published and registered in the European Society for Immunodeficiencies registry (www.esid.org), Gathmann et al 18 have reported a clinical description of 2212 adults with CVID (including proportion of chronic complications and some selfreported outcomes) without assessment of severity. Recently, in a survey conducted by the Immune Deficiency Foundation, Seeborg et al 20 have reported the perceived health among patients with PIDs, in which 39% of the patients perceived their health status as fair/very poor.
Although few studies have assessed the severity of health conditions in patients with PID, many studies have been carried out to evaluate HRQoL among adults with PIDs, although almost exclusively in patients receiving chronic immunoglobulin replacement therapy. 10, 21, 22 In our study we detected statistically significant impairments in all domains of quality of life in adults with PID. Moreover, we specifically assessed the effect of health condition burden on HRQoL and found a highly significant decrease in all composite scores and subscales in patients who experienced additional health conditions. Notably, we did not detect major differences in HRQoL domains when comparing patients according to PID diagnosis, except among patients with immune dysregulation, who displayed high scores in both mental health and general health. However, this might reflect merely a low statistical power of comparison caused by the relatively small patient numbers in each diagnostic subgroup. Duration of disease did not affect the patient's quality of life, unlike recent hospitalization events, which suggests that self-reported HRQoL is probably strongly influenced by recent events.
Interestingly, patients who underwent HSCT scored significantly higher with respect to general health and physical composite scores, thereby suggesting that the post-HSCT group had a better HRQoL than the nontransplanted group. This observation appears quite unexpected because cases of patients with PIDs undergoing transplanted are more severe than those of patients not undergoing transplantation. However, this feature should be interpreted with caution because it might reflect only the curative potential of HSCT. The significant impairment of HRQoL described in our PID cohort has also been reported in other patients with severe chronic childhood disease who reached adulthood. Notably, this has been described in patients with cystic fibrosis, juvenile chronic arthritis, and type 1 diabetes. [23] [24] [25] [26] [27] [28] In conclusion, our results quantify the magnitude of health conditions in adults living with PIDs diagnosed during childhood. Our findings clearly emphasize the need to closely monitor this vulnerable population and the importance of multidisciplinary health care teams. 
